Capecitabine as salvage treatment in relapsed nasopharyngeal carcinoma: a phase II study.
E Ciuleanu, A Irimie, TE Ciuleanu, V Popita… - Journal of BU ON …, 2008 - europepmc.org
E Ciuleanu, A Irimie, TE Ciuleanu, V Popita, N Todor, N Ghilezan
Journal of BU ON.: Official Journal of the Balkan Union of Oncology, 2008•europepmc.org… To evaluate the efficacy of capecitabine (Xeloda) as rescue treatment (2nd, 3rd and 4th
line) in patients with relapsed nasopharyngeal carcinoma (NPC) in a phase II study. …
Capecitabine is active in relapsed NPC patients, achieving 48% objective responses, with
mild toxicity. It is an attractive therapy to be administered in an outpatient setting. …
line) in patients with relapsed nasopharyngeal carcinoma (NPC) in a phase II study. …
Capecitabine is active in relapsed NPC patients, achieving 48% objective responses, with
mild toxicity. It is an attractive therapy to be administered in an outpatient setting. …
Purpose
To evaluate the efficacy of capecitabine (Xeloda) as rescue treatment (2nd, 3rd and 4th line) in patients with relapsed nasopharyngeal carcinoma (NPC) in a phase II study.
europepmc.org
以上显示的是最相近的搜索结果。 查看全部搜索结果